Privo Technologies Inc. is committed to advancing cancer treatment through innovative nanotechnology-based formulations. We are currently conducting an innovative Phase 2/3 Run In, Open-Label, Two Arm Study for Safety, Efficacy and Tolerability of PRV111 (Cisplatin Transmucosal System) & PRV211 (Intraoperative Cisplatin System) in subjects amenable to surgery.

CLN-004:  Study Details | Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma | ClinicalTrials.gov

The CLN-004 study is investigating two promising treatment platforms:

• ARM 1: PRV111 (Topical Cisplatin Transmucosal System): Evaluates PRV111, a nanoengineered, self-adhesive patch designed for the topical delivery of cisplatin directly to the tumor site. This arm targets patients with carcinoma in situ (CIS) and high-grade dysplasia of the oral cavity, aiming to improve local control and potentially reduce the extent of surgical intervention
• Arm 2: PRV211 (Intraoperative Cisplatin System): Assesses PRV211, an intraoperative chemotherapy system intended for application into the resected tumor bed during surgery. This approach seeks to eliminate residual microscopic disease and reduce the risk of tumor recurrence in patients with stages T1-T4 HNSCC

Why Participate?

• Access to an investigational localized treatment aimed at reducing the need for extensive surgery
• Close monitoring and care from leading cancer centers
• Contribution to advancing future treatment options for oral cavity cancers

Active Clinical Trial Sites

Patients are currently being enrolled at the following prestigious institutions:

• University of Chicago Medicine (Chicago, IL)
• City of Hope (Los Angeles, CA)
• Miami Cancer Institute (Miami, FL)
• Cleveland Clinic (Cleveland, OH)

Each site has a specialized clinical team experienced in head and neck cancers who can determine if you may be eligible for participation.

For detailed information about our previous Phase 2 trial (CLN-001), please visit this link.